Current Heart Failure Reports最新文献

Sex Differences in Chagas Cardiomyopathy: a Comprehensive Review. 查加斯心肌病的性别差异：一项综合综述。

IF 3.4

Current Heart Failure Reports Pub Date : 2025-10-13 DOI: 10.1007/s11897-025-00718-9

Antonio de Padua Mansur, Edecio Cunha-Neto, Reinaldo Bulgarelli Bestetti, Pauline Brochet, Christophe Chevillard, Antonio Carlos Pereira-Barretto, Edimar Alcides Bocchi

{"title":"Sex Differences in Chagas Cardiomyopathy: a Comprehensive Review.","authors":"Antonio de Padua Mansur, Edecio Cunha-Neto, Reinaldo Bulgarelli Bestetti, Pauline Brochet, Christophe Chevillard, Antonio Carlos Pereira-Barretto, Edimar Alcides Bocchi","doi":"10.1007/s11897-025-00718-9","DOIUrl":"https://doi.org/10.1007/s11897-025-00718-9","url":null,"abstract":"Purpose of review: Chagas cardiomyopathy (CCC) is a major cause of heart failure (HF) in Latin America, yet sex-specific differences in HF presentation and outcomes remain underexplored. This review summarizes current knowledge on clinical manifestations, HF phenotypes, and molecular mechanisms in women and men with CCC.Recent findings: Men with CCC more frequently present with severe HF, arrhythmias, and sudden cardiac death, whereas women often exhibit nonspecific symptoms such as fatigue and palpitations. HF prevalence in women is variable, with some cohorts showing lower left ventricular systolic dysfunction in women. Among women with CCC-HF, 41% have HFrEF, 20% HFmrEF, and 39% HFpEF. Dyspnea affects 29% of women, approximately half the male rate. Comorbidities are generally similar, though chronic kidney disease is less common in women. Molecular and transcriptomic studies indicate that males exhibit stronger Th1 inflammatory signatures, while females show enrichment of Th2 and Treg cells, correlating with disease severity. Women with CCC tend to experience milder HF phenotypes and slower progression, potentially due to hormonal and immune-mediated mechanisms, highlighting the need for sex-specific evaluation and management strategies in CCC.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"27"},"PeriodicalIF":3.4,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145279141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Instruments to Measure Frailty in Patients with Heart Failure: a Narrative Review. 测量心力衰竭患者虚弱程度的仪器：叙述性回顾。

IF 3.4

Current Heart Failure Reports Pub Date : 2025-10-03 DOI: 10.1007/s11897-025-00716-x

Cristiana Vitale, Ilaria Spoletini, Walter Gianni, Giuseppe Mc Rosano, Camilla Hage

{"title":"Instruments to Measure Frailty in Patients with Heart Failure: a Narrative Review.","authors":"Cristiana Vitale, Ilaria Spoletini, Walter Gianni, Giuseppe Mc Rosano, Camilla Hage","doi":"10.1007/s11897-025-00716-x","DOIUrl":"https://doi.org/10.1007/s11897-025-00716-x","url":null,"abstract":"Purpose of review: Frailty is a common multidimensional syndrome in patients with heart failure (HF); it is associated with worse outcomes, including poor quality of life, disability, hospitalizations, and increased mortality. This narrative review critically summarizes the most widely used instruments in clinical practice for frailty assessment in HF, compares their strengths and limitations, and discusses their role in predicting adverse outcomes.Recent findings: Various tools have been developed to assess frailty in the HF patient population, aiming to guide clinical decisions and improve patient management. These scoring systems vary in their complexity and applicability and follow two main different approaches (the Fried phenotype and the frailty index). Recently, a new Heart Failure Frailty Score (HFFS) specifically designed to assess frailty in HF patients has been proposed. Frailty is a critical prognostic modifier in HF, making its systematic assessment in clinical practice essential for guiding therapeutic decision-making and optimizing clinical outcomes in this vulnerable population.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"26"},"PeriodicalIF":3.4,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Worsening Renal Function in Acute Heart Failure: Not Always Harmful. 急性心力衰竭时肾功能恶化：并不总是有害的。

IF 3.4

Current Heart Failure Reports Pub Date : 2025-09-26 DOI: 10.1007/s11897-025-00714-z

Yukihiro Watanabe, Yoshiaki Kubota, Kuniya Asai

引用次数: 0

Recharging the Powerhouse: Mitochondrial Dysfunction and Therapy in Cardiorenal Syndrome Type 4. 充电动力：4型心肾综合征的线粒体功能障碍和治疗。

IF 3.4

Current Heart Failure Reports Pub Date : 2025-09-13 DOI: 10.1007/s11897-025-00713-0

Edouard Long, Joshua M Heihre

{"title":"Recharging the Powerhouse: Mitochondrial Dysfunction and Therapy in Cardiorenal Syndrome Type 4.","authors":"Edouard Long, Joshua M Heihre","doi":"10.1007/s11897-025-00713-0","DOIUrl":"10.1007/s11897-025-00713-0","url":null,"abstract":"Purpose of review: Cardiorenal syndrome type 4 (CRS-4) is characterised by the development of cardiac dysfunction secondary to chronic kidney disease (CKD). This review outlines the pathophysiology of CRS-4, with a focus on the emerging role of mitochondrial dysfunction, and evaluates novel mitochondria-targeting therapeutics for CRS-4.Recent findings: Current research has positioned mitochondrial dysfunction in cardiomyocytes as a key driver of CRS-4 pathophysiology, characterised by impaired adenosine triphosphate production, increased reactive oxygen species (ROS) generation, dysregulated mitophagy, altered mitochondrial biogenesis and dynamics, and bioenergetic malfunction. Currently licensed drugs, such as dapagliflozin and sacubitril/valsartan, have demonstrated mitoprotective effects in CRS-4, and numerous other therapies targeting mitochondria have proven efficacious in preclinical studies. However, real-world clinical trials are required to determine whether mitochondria represent a viable therapeutic target that offers meaningful clinical benefits to patients with CKD. There is increasing evidence that mitochondrial dysfunction is a key pathomechanism in the development of CRS-4. Mitochondrial-targeting therapies offer a novel mechanism-driven approach, with numerous showing preclinical promise. However, real-world clinical trials are required to determine their therapeutic potential.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"24"},"PeriodicalIF":3.4,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145052114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When the Heart, Kidneys, and Body Waste Away: A Review of Cachexia in Cardiorenal Syndrome. 当心脏、肾脏和身体消耗：心肾综合征恶病质的综述。

IF 3.4

Current Heart Failure Reports Pub Date : 2025-08-28 DOI: 10.1007/s11897-025-00711-2

Kunaal S Sarnaik, Saeid Mirzai

{"title":"When the Heart, Kidneys, and Body Waste Away: A Review of Cachexia in Cardiorenal Syndrome.","authors":"Kunaal S Sarnaik, Saeid Mirzai","doi":"10.1007/s11897-025-00711-2","DOIUrl":"https://doi.org/10.1007/s11897-025-00711-2","url":null,"abstract":"Purpose of review: Cardiorenal syndrome refers to disorders of the heart and kidneys in which dysfunction in one organ has resulted in dysfunction of the other. Wasting continuum disorders such as cachexia are highly prevalent in cardiorenal syndrome, yet the clinical impact, pathophysiological mechanisms, and management options have not been well elucidated in previous literature. In this review, we aim to summarize current knowledge regarding the epidemiology, clinical impact, and pathophysiology of CRS-induced wasting continuum disorders, as well as highlight effective and potentially emerging treatment options.Recent findings: Neurohormonal activation, inflammation, metabolic dysfunction, gastrointestinal abnormalities, protein degradation, and mitochondrial pathway dysfunction are pathophysiologic mechanisms underlying CRS-induced cachexia. Recent studies have investigated various treatment options targeting such mechanisms with mixed results. Early screening of wasting continuum disorders in CRS, in combination with nutritional supplementation and exercise rehabilitation strategies, is the mainstay of management. Pharmacologic optimization may also benefit patients. Future studies are necessary to improve generalizability and consensus definitions of cardio- and renal-specific wasting continuum disorders.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"23"},"PeriodicalIF":3.4,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relative Fat Mass: Refining Adiposity Measurement in the Era Beyond Body Mass Index. 相对脂肪量：在超越身体质量指数的时代改进脂肪测量。

IF 3.8

Current Heart Failure Reports Pub Date : 2025-07-19 DOI: 10.1007/s11897-025-00709-w

Navin Suthahar, Emily S Lau, Gianluigi Savarese

{"title":"Relative Fat Mass: Refining Adiposity Measurement in the Era Beyond Body Mass Index.","authors":"Navin Suthahar, Emily S Lau, Gianluigi Savarese","doi":"10.1007/s11897-025-00709-w","DOIUrl":"10.1007/s11897-025-00709-w","url":null,"abstract":"Purpose of review: To position relative fat mass (RFM) as a more accurate, physiologically grounded, and clinically useful alternative to body mass index (BMI) for assessing adiposity and predicting cardiometabolic risk, including heart failure. RECENT FINDINGS: RFM estimates body fat percentage using a sex-specific formula based on waist circumference and height. RFM not only correlates more strongly with fat mass than BMI, but also shows a weaker correlation with muscle mass. This distinction helps reduce lean mass-related confounding in the assessment of adiposity. In clinical studies, RFM has emerged as a robust predictor of incident heart failure, cardiometabolic disease, and all-cause mortality. RFM avoids misclassification of adiposity in individuals with high muscle mass and better reflects abdominal adiposity than BMI. As the prevalence of heart failure and other obesity-related diseases continues to rise, RFM offers a practical and intuitive tool for assessment of adiposity and heart failure risk - challenging the long-standing dominance of BMI.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"22"},"PeriodicalIF":3.8,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Multisensor CIED-based Heart Failure Monitoring on Mortality, Heart Failure Hospitalizations and Outpatient Visits: A Systematic Review. 基于cied的多传感器心力衰竭监测对死亡率、心力衰竭住院和门诊就诊的影响：一项系统综述。

IF 3.8

Current Heart Failure Reports Pub Date : 2025-07-01 DOI: 10.1007/s11897-025-00707-y

Bert A C Zwaenepoel, Annefleur Kluft, Michelle Feijen, Jan W Schoones, Ward A Heggermont, Anastasia D Egorova, Saskia L M A Beeres

{"title":"Impact of Multisensor CIED-based Heart Failure Monitoring on Mortality, Heart Failure Hospitalizations and Outpatient Visits: A Systematic Review.","authors":"Bert A C Zwaenepoel, Annefleur Kluft, Michelle Feijen, Jan W Schoones, Ward A Heggermont, Anastasia D Egorova, Saskia L M A Beeres","doi":"10.1007/s11897-025-00707-y","DOIUrl":"10.1007/s11897-025-00707-y","url":null,"abstract":"Purpose of review: Cardiac Implantable Electronic Device (CIED)-based remote monitoring has been proposed to improve heart failure (HF) management by enabling early detection of decompensation. This systematic review evaluates the effectiveness of multisensor CIED-based monitoring in reducing mortality, HF hospitalizations, and unplanned HF outpatient visits.Recent findings: Earlier CIED-based remote monitoring strategies were mainly based on single-sensor impedance-based algorithms, and showed limited clinical benefits. Newer multisensor CIED-based algorithms have shown promise in initial studies. However, their impact on clinical outcomes remains uncertain, and therefore current HF guidelines provide limited recommendations. Multisensor CIED-based algorithms reliably identify high-risk HF patients and their use leads to reductions in HF hospitalizations and unplanned outpatient HF visits, although prospective validation in RCTs is lacking for any of the algorithms. Standardized response strategies are needed to enhance clinical integration and generalizability. If validated, multisensor monitoring could become a key tool in HF management.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"21"},"PeriodicalIF":3.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12213901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening and Needs Assessment Tools for Palliative Care in Patients with Cardiovascular Disease: Narrative Review. 心血管疾病患者姑息治疗的筛查和需求评估工具：叙述性综述

IF 3.8

Current Heart Failure Reports Pub Date : 2025-06-30 DOI: 10.1007/s11897-025-00708-x

Angela Iurlaro, Eleonora Meloni, Basile Mouhat, Graziano Onder, Fiona Ecarnot

{"title":"Screening and Needs Assessment Tools for Palliative Care in Patients with Cardiovascular Disease: Narrative Review.","authors":"Angela Iurlaro, Eleonora Meloni, Basile Mouhat, Graziano Onder, Fiona Ecarnot","doi":"10.1007/s11897-025-00708-x","DOIUrl":"https://doi.org/10.1007/s11897-025-00708-x","url":null,"abstract":"Purpose of review: There is a growing need for palliative care (PC) among patients with cardiovascular disease (CVD), as population ageing and technological progress bolster the numbers of patients living with chronic forms of CVD.Recent findings: PC can provide support and benefits in areas that are not necessarily addressed by medical therapy. However, many healthcare providers, and cardiologists in particular, struggle with identifying the right time to introduce PC in the care trajectory of patients with CVD, especially in heart failure, where the clinical course is punctuated by highs and lows, with periods of stability that may last several months to years. The use of validated assessment tools to recognize PC needs of people living with CVD is recommended, but clinicians may be unaware of existing instruments and criteria for PC referral, or when and how to use them. We report here a narrative review of the literature, with the aim of providing an overview of useful tools for the identification and assessment of palliative care needs among patients suffering from cardiovascular disease with a view to improving their care process. We further discuss the overall suitability of available tools, as well as issues specifically related to implantable cardiac devices at the end-of-life.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"20"},"PeriodicalIF":3.8,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies. 心源性休克的肾功能障碍：机制、临床意义和治疗策略。

IF 3.8

Current Heart Failure Reports Pub Date : 2025-06-25 DOI: 10.1007/s11897-025-00706-z

Diana De Oliveira-Gomes, Christian Guilliod, Ilan Vavilin, Ankeet Bhatt, Brendon Neuen, Jamie L W Kennedy, Manreet Kanwar, Megan Terek, Shashank S Sinha, Van-Khue Ton, Mitchell Psotka, Vanessa Blumer

{"title":"Renal Dysfunction Across the Spectrum of Cardiogenic Shock: Mechanisms, Clinical Implications, and Therapeutic Strategies.","authors":"Diana De Oliveira-Gomes, Christian Guilliod, Ilan Vavilin, Ankeet Bhatt, Brendon Neuen, Jamie L W Kennedy, Manreet Kanwar, Megan Terek, Shashank S Sinha, Van-Khue Ton, Mitchell Psotka, Vanessa Blumer","doi":"10.1007/s11897-025-00706-z","DOIUrl":"https://doi.org/10.1007/s11897-025-00706-z","url":null,"abstract":"Purpose of review: This review aims to elucidate the complex interplay between cardiogenic shock (CS) and renal function, detailing the mechanisms of kidney injury, identifying risk factors, and providing a framework for the diagnosis and management of acute kidney injury (AKI) in CS. We evaluate evidence supporting medical interventions, including vasopressors, inotropes, and mechanical circulatory support (MCS), in relation to renal outcomes.Recent findings: AKI affects up to 80% of patients with CS and is associated with higher mortality, especially when Renal Replacement Therapy (RRT) is required. Mechanisms include impaired perfusion, venous congestion, and systemic inflammation. Invasive hemodynamic assessment improves diagnostic accuracy. Continuous RRT is preferred in unstable patients, although early initiation has not been shown to provide a survival benefit. Emerging tools such as novel biomarkers and machine learning may aid in early detection and risk stratification. AKI in CS is common and multifactorial, with significant prognostic impact. Early recognition, hemodynamic optimization, and a multidisciplinary strategy remain essential. Future work should focus on individualized management approaches to improve outcomes.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"19"},"PeriodicalIF":3.8,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and Outcomes of Fears in Advanced Heart Failure: Differences Across Disease Stages. 晚期心力衰竭患者恐惧的患病率和结果：不同疾病阶段的差异

IF 3.8

Current Heart Failure Reports Pub Date : 2025-05-17 DOI: 10.1007/s11897-025-00705-0

Mats Westas, Semyon Melnikov

{"title":"Prevalence and Outcomes of Fears in Advanced Heart Failure: Differences Across Disease Stages.","authors":"Mats Westas, Semyon Melnikov","doi":"10.1007/s11897-025-00705-0","DOIUrl":"10.1007/s11897-025-00705-0","url":null,"abstract":"Purpose of review: Heart failure (HF) is a complex, multifactorial syndrome resulting from impaired heart function. When medical management of HF is ineffective, mechanical circulatory support with a left-ventricular assist device (LVAD) or heart transplantation are the only options for significantly extending patients' lives. Patients with HF experience various emotional reactions, including fears, which may impact their well-being44444 and disease management. Understanding how fears may differentially influence patients with HF depending on the stage of the disease is thus essential for delivering personalized care.Recent findings: Among patients with advanced HF, disease-related and existential fears were associated with anxiety, depression, sleeplessness, loss of dignity, feelings of abandonment, uncertainty about the future, and restricted physical and social activities. The fears of patients with LVAD can be categorized into device-related, transplant-related, and psychological/emotional fears. Device-related fears involved maintaining the device in optimal condition, transplant-related fears included not surviving until transplantation or not receiving an organ, and psychological/emotional fears related to sexuality and disease progression, correlating with anxiety and depression. The fears experienced by heart transplant recipients fall into three main categories: avoidance, existential, and psychological fears. Avoidance fears lead to lower exercise motivation and higher anxiety, existential fears involved the fear of death leading to poor psychological well-being, and psychological fears included concerns about non-compliance repercussions, hypochondriacal responses, and appearing ungrateful. Each stage of HF disease presents unique fears with distinct implications, emphasizing the need for stage-specific psychological support and interventions. Further studies are required to understand the impact of fears in different stages of HF disease.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"18"},"PeriodicalIF":3.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12085343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0